# The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)

> **NCT05659654** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 95 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ursodeoxycholic acid

## Key facts

- **NCT ID:** NCT05659654
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-16
- **Primary completion:** 2023-03-03
- **Final completion:** 2023-03-08
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05659654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05659654, "The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05659654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*